Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ROP Clear all
Terminated No phase listed Observational

Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project

NCT02257307
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
RetCam retinal imaging used for routine care
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
32 Weeks to 40 Weeks
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Baltimore, Maryland • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 22, 2026, 9:21 PM EDT
Not listed Phase 2Phase 3 Interventional

The Early Treatment for Retinopathy of Prematurity Study (ETROP)

NCT00027222
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
retinal ablation
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
0 Years to 42 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
26
States / cities
Palo Alto, California • San Francisco, California • Chicago, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Jul 22, 2026, 9:21 PM EDT
Not listed Phase 2Phase 3 Interventional

Cysteine Supplementation in Critically Ill Neonates

NCT00254176
View directory record Official record
Conditions
Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
Interventions
Parenteral cysteine-HCl supplementation, Placebo - added premasol
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 30 Days
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Jul 22, 2026, 9:21 PM EDT
Completed No phase listed Observational

ROP Check Database Premature Infant Outcomes

NCT07312669
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Not listed
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
Not listed
Enrollment
7,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 22, 2026, 9:21 PM EDT
Recruiting Phase 1 Interventional

Safety, PK and PD of FLQ-101 in Premature Neonates

NCT07093255
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
FLQ-101
Drug
Lead sponsor
FELIQS INC.
Industry
Eligibility
4 Days to 5 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Not applicable Interventional

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

NCT00000133
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Trans-scleral Cryotherapy
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Up to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 2003
U.S. locations
24
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"

NCT01860534
View directory record Official record
Conditions
Light Sensitivity
Interventions
eye covers
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Jul 22, 2026, 9:21 PM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Automated Screening Device to Detect MTMROP

NCT06517836
View directory record Official record
Conditions
Retinopathy of Prematurity, ROP
Interventions
iROP DL
Device
Lead sponsor
Siloam Vision
Industry
Eligibility
4 Weeks to 2 Years
Enrollment
1,284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 22, 2026, 9:21 PM EDT
Terminated No phase listed Observational

ROP Screening: Comparison of Pain Using Two Eyelid Retractors

NCT02152046
View directory record Official record
Conditions
Pain During ROP Exam
Interventions
ROP exam with spring loaded retractor, ROP exam with screw retractor
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
23 Weeks to 37 Weeks
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 9:21 PM EDT
No Longer Available No phase listed Expanded access

Use of Pan-vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

NCT00870636
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab (Avastin)
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
30 Weeks and older
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Phase 3 Interventional Results available

Rainbow Extension Study

NCT02640664
View directory record Official record
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 22, 2026, 9:21 PM EDT
Terminated Not applicable Interventional

Use of Sucrose to Relieve Pain During Eye Exams in Infants

NCT00161694
View directory record Official record
Conditions
Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions
sucrose solution
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
5 Weeks and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2008 · Synced Jul 22, 2026, 9:21 PM EDT
Completed No phase listed Observational

Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity

NCT01780155
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Retinopathy of Prematurity, Prematurity, Pulmonary Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
Not listed
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 22, 2026, 9:21 PM EDT
Terminated No phase listed Observational

A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity

NCT01335113
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Omegaven, Standard lipids (primarily omega-6 fatty acids)
Drug · Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Jul 22, 2026, 9:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analyzing Retinal Microanatomy in ROP

NCT02887157
View directory record Official record
Conditions
Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
Interventions
Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection
Device · Other
Lead sponsor
Duke University
Other
Eligibility
30 Weeks and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
4
States / cities
Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jul 22, 2026, 9:21 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

NCT04634604
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab, Laser
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 9:21 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 22, 2026, 9:21 PM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab Treatment For Type 1 ROP

NCT04634578
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Bevacizumab
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
25
States / cities
Little Rock, Arkansas • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Phase 3 Interventional

The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)

NCT00000156
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Goggles, Ambient Light Reduction
Device · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Up to 1 Day
Timeline
Started 1995
U.S. locations
3
States / cities
Buffalo, New York • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2006 · Synced Jul 22, 2026, 9:21 PM EDT
Recruiting Phase 2 Interventional

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions
OHB-607
Drug
Lead sponsor
OHB Neonatology Ltd.
Industry
Eligibility
0 Hours to 24 Hours
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
26
States / cities
Little Rock, Arkansas • California City, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 9:21 PM EDT
Completed Phase 2 Interventional Results available

Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)

NCT02344225
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Caffeine citrate, Ibuprofen, Ketorolac
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
Up to 28 Weeks
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jul 22, 2026, 9:21 PM EDT